Patrick Baeuerle
Founder at iOmx Therapeutics AG
Net worth: 7 M $ as of 2024-03-30
Profile
Patrick A.
Baeuerle is the founder of Maverick Therapeutics, Inc. (founded in 2016), Werewolf Therapeutics, Inc. (founded in 2017), Harpoon Therapeutics, Inc. (founded in 2015), iOmx Therapeutics AG (founded in 2016), TCR2 Therapeutics, Inc. (founded in 2015), Cullinan Oncology LLC (founded in 2016), and Cullinan Oncology, Inc. (founded in 2016).
Dr. Baeuerle currently holds positions at TeGenero AG as a Director since 2009, MPM BioImpact, Inc as an Executive Partner since 2015, European Molecular Biology Organization as a Member, and Crossbow Therapeutics, Inc. as a Chief Scientific Officer.
Dr. Baeuerle has held former positions at the University of Freiburg as Chairman-Biochemistry & Professor from 1994 to 1996, Tularik, Inc. as Director-Drug Discovery from 1996 to 1998, F.
Hoffmann-La Roche Ltd.
as Head-Global Business from 1998 to 2000, Micromet AG as Chief Scientific Officer from 1998 to 2012, Amgen Research (Munich) GmbH as Vice President-Research & General Manager from 2012 to 2015, and Amgen Rockville, Inc. as Chief Scientific Officer & Senior Vice President from 1998 to 2012.
Dr. Baeuerle's education includes a doctorate from Max-Planck-Institute for Molecular Genetics and undergraduate and doctorate degrees from Ludwig-Maximilians-Universität München (conferred in 1987).
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-02-16 | 417,434 ( 0.97% ) | 7 M $ | 2024-03-30 |
Patrick Baeuerle active positions
Companies | Position | Start |
---|---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Director/Board Member | - |
European Molecular Biology Organization | Corporate Officer/Principal | 2010-05-12 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Founder | 2016-02-29 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2015-03-31 |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Chief Tech/Sci/R&D Officer | - |
Former positions of Patrick Baeuerle
Companies | Position | End |
---|---|---|
CULLINAN THERAPEUTICS, INC. | Founder | 2023-06-07 |
TCR2 THERAPEUTICS INC. | Founder | 2021-08-23 |
HARPOON THERAPEUTICS, INC. | Founder | 2020-06-29 |
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The private company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Chief Tech/Sci/R&D Officer | 2015-02-28 |
░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Patrick Baeuerle
Max-Planck-Institute for Molecular Genetics | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
HARPOON THERAPEUTICS, INC. | Health Technology |
WEREWOLF THERAPEUTICS, INC. | Health Technology |
CULLINAN THERAPEUTICS, INC. | Health Technology |
Private companies | 13 |
---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Health Technology |
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The private company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Producer Manufacturing |
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
European Molecular Biology Organization | |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Health Technology |
- Stock Market
- Insiders
- Patrick Baeuerle